Lakefront Biotherapeutics NV current report, Q1 FY2026

SEC Filing Summary: Form 6-K

Business Context and Reporting Period

This Form 6-K is filed by Galapagos NV (a foreign private issuer), not Lakefront Biotherapeutics NV as indicated in the request metadata. The filing covers the month of February 2026 and reports on a press release issued on February 23, 2026. The registrant is headquartered in Mechelen, Belgium, and files annual reports on Form 20-F.

Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document serves solely to incorporate a press release by reference and does not contain a financial statement or quantitative performance data.

Material Changes

No material financial changes versus a prior comparable period are detailed in the provided text. The filing references a press release (Exhibit 99.1) but does not summarize its specific content regarding operational or financial shifts.

Guidance, Outlook, and Risks

The filing text does not provide specific guidance, outlook, management commentary, risks, contingencies, or unusual items. It notes that quotes from Henry Gosebruch and Aaron Cox in the attached press release are not incorporated by reference into the Company's Registration Statements on Form S-8.

Key Facts for Investor Verification

  • Verify the correct registrant name: The filing is for Galapagos NV, not Lakefront Biotherapeutics NV.
  • Review the attached Exhibit 99.1 (Press Release dated February 23, 2026) for the actual substance of the announcement, as the Form 6-K text contains no operational details.
  • Confirm that the press release content is not incorporated into Form S-8 registration statements, except for specific quotes which are explicitly excluded.
  • Note that no financial metrics are disclosed in this specific filing document.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.